Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)

Next Previous
Trial Profile

A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depemokimab (Primary)
  • Indications Nasal polyps; Rhinosinusitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ANCHOR-2
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

  • 06 Jan 2026 According to GSK media release, based on data from SWIFT-1 and 2 and ANCHOR-1 and 2 trials, Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Exdensur (depemokimab) for severe asthma and chronic rhinosinusitis with nasal polyps. It becomes the first and only ultra-long-acting biologic in Japan.
  • 12 Dec 2025 According to GSK media release, company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of depemokimab in chronic rhinosinusitis with nasal polyps.The European Commission decision on approval is expected in Q1 2026.
  • 15 Sep 2025 According to GSK media release, company will present data from this study at the upcoming ERS Congress 2025, from 27 September to 1 October in Amsterdam, the Netherlands.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top